Translate Bio (OTC:TBIO) has a major catalyst that is approaching towards the end of October of 2019. This will be both an oral and poster presentation of phase 1/2 study data from about 12 patients with cystic fibrosis (CF). These results will be presented on November 1, 2019, at the 33rd Annual North American Cystic Fibrosis Conference (NACFC) taking place in Nashville, Tennessee from October 31 to November 2, 2019. This can be data that has already been released back in July of 2019, along with possible updated data since then. And that's not all. Multi-ascending dose data from this phase 1/2 study will be reported in 2020. That sets up a catalyst at the end of this month and then another one likely in 2020. The company has a solid pipeline, and I believe a lot of value exists with the cystic fibrosis treatment of MRT5005. This product is intended to be used for CF and other lung diseases.
Cystic Fibrosis Treatment Using MRT5005
Cystic Fibrosis is a hereditary disease that primarily affects the lungs and can also be bothersome for the digestive system as well. I think the most important item you should know is that it can be life-threatening to the patient. The reason why is because thick and sticky mucus can start to clog up the lungs. There are many issues with sweat, mucus, and digestive juices that clog up tubes and the various systems that exist within the body. The most common symptoms for these patients is cough and recurrent lung infections. Because the lungs clog up with mucus, they become weak/blocked and there is always a chance for opportunistic serious lung infections that take place. That's why it is said that these patients have a shorter than normal life span. The main reason why this disease occurs is that there exists a mutation on
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.
